n
u
n
l
g
por
lo
gener
son
indistingu
de
lo
viru
de
lo
que
proceden
su
empleo
como
presenta
important
ventaja
en
de
seguridad
la
vlp
pueden
inducir
una
fuert
respuesta
inmun
tanto
humor
como
celular
se
ha
demostrado
que
poseen
capacidad
de
actuar
como
adyuvant
selfadjuv
de
su
idoneidad
como
vacuna
frent
al
viru
del
cual
proceden
la
vlp
se
pueden
utilizar
como
vector
para
la
de
la
vlp
han
mostrado
una
elevada
eficacia
como
candidato
vacunal
sin
embargo
hasta
el
momento
una
vacuna
basada
en
vlp
ha
sido
autorizada
comercializada
en
el
campo
veterinario
en
est
trabajo
se
revisa
el
estado
actual
de
la
vlp
empleada
como
nueva
estrategia
vacunal
en
el
campo
de
la
veterinaria
analizando
la
potencial
ventaja
que
enfrenta
esta
vaccin
consid
one
effect
way
control
pathogen
prevent
diseas
human
well
veterinari
field
tradit
vaccin
anim
viral
diseas
base
inactiv
attenu
virus
new
subunit
vaccin
gain
attent
research
anim
vaccinolog
among
viruslik
particl
vlp
repres
one
appeal
approach
open
interest
frontier
anim
vaccin
vlp
robust
protein
scaffold
exhibit
welldefin
geometri
uniform
mimic
overal
structur
nativ
virion
lack
viral
genom
often
antigen
indistinguish
viru
deriv
present
import
advantag
term
safeti
vlp
stimul
strong
humor
cellular
immun
respons
shown
exhibit
selfadjuv
abil
addit
suitabl
vaccin
homolog
viru
deriv
vlp
also
use
vector
multimer
present
foreign
antigen
vlp
therefor
shown
dramat
effect
candid
vaccin
nevertheless
one
veterinari
vlpbase
vaccin
licens
review
examin
detail
current
statu
vlp
vaccin
strategi
veterinari
field
discuss
potenti
advantag
challeng
technolog
sociedad
de
publish
elsevi
sl
right
reserv
palabra
clave
vacuna
veterinaria
vector
vacunal
r
e
u
e
n
la
constituy
uno
de
lo
procedimiento
eficac
para
controlar
lo
prevenir
enfermedad
tanto
en
sere
humano
como
en
el
campo
veterinario
la
vacuna
tradicional
frent
enfermedad
animal
se
basan
por
lo
gener
en
la
de
viru
atenuado
inactivado
sin
embargo
la
vacuna
de
subunidad
ganando
terreno
progresivament
en
el
campo
de
la
sanidad
anim
entr
ella
la
vacuna
basada
en
viral
vlp
por
su
nombr
en
viruslik
particl
representan
una
de
la
estrategia
atractiva
actualment
en
el
campo
de
la
vacuna
para
animal
la
vlp
son
estructura
proteica
con
una
uniformidad
muy
definida
que
mimetizan
la
estructura
de
lo
viru
nativo
pero
carecen
de
genoma
viral
vaccin
consid
costeffect
way
control
pathogen
prevent
diseas
human
veterinari
field
current
major
licens
vaccin
anim
either
live
attenu
kill
develop
use
convent
technolog
howev
new
subunit
vaccin
get
foothold
veterinari
vaccinolog
among
viruslik
particl
vlp
repres
one
appeal
approach
due
intrins
immunogen
properti
well
high
safeti
profil
highlight
sever
review
appear
last
ten
year
viruslik
particlebas
vaccin
vlp
vaccin
combin
mani
advantag
wholeviru
vaccin
recombin
subunit
vaccin
integr
key
featur
underlay
immunogen
safeti
protect
potenti
fig
particul
multival
natur
b
welldefin
geometri
remark
uniform
repetit
order
surfac
structur
c
preserv
nativ
antigen
conform
safeti
absolut
noninfecti
non
replic
candid
e
higher
stabil
solubl
antigen
extrem
environment
condit
f
applic
vector
present
foreign
antigen
ligand
drug
g
amen
fulfil
differenti
infect
vaccin
anim
diva
complianc
concern
vlp
supramolecular
assemblag
welldefin
geometri
usual
icosahedron
rodlik
structur
diamet
rang
nm
mimic
overal
structur
nativ
virion
protein
cage
base
natur
intrins
abil
mani
type
structur
viral
subunit
frequent
major
protein
capsid
envelop
spontan
self
assembl
vlp
express
use
recombin
express
system
compos
multipl
copi
one
viral
protein
usual
antigen
indistinguish
infecti
viru
subvir
particl
multival
display
highli
order
structur
vlp
constitut
pathogenassoci
molecular
pattern
motif
pamp
sinc
motif
larg
uniqu
microbi
antigen
mammalian
immun
system
highli
repetit
surfac
structur
selfadjuv
evolv
respond
vigor
arrang
antigen
pamp
trigger
innat
immun
sens
mechan
recogn
tolllik
receptor
tlr
well
patternrecognit
receptor
prr
present
host
cell
addit
due
highli
repetit
surfac
vlp
shown
induc
strong
b
cell
respons
effici
crosslink
membraneassoci
immunoglobulin
molecul
constitut
bcell
receptor
stimul
b
cell
vlp
instanc
strong
enough
elicit
cellindepend
induct
igm
antibodi
henc
exampl
vlp
act
tcell
independ
b
cell
antigen
besid
pamp
also
stimul
antigen
uptak
antigen
present
cell
apc
subsequ
present
antigen
cell
adapt
immun
respons
beyond
pamp
properti
particul
natur
dimens
entail
vlp
protein
subunit
may
effici
uptaken
apc
particular
dendrit
cell
dc
uptak
antigen
apc
depend
upon
differ
properti
includ
size
shape
surfac
charg
etc
antigen
size
key
factor
apc
abl
uptak
antigen
pathogenlik
dimens
nm
demonstr
dc
optim
uptak
antigen
diamet
approxim
nm
within
rang
vlp
size
fact
vlp
present
overal
suitabl
characterist
uptak
dc
subsequ
process
present
mhcii
mhci
crosspresent
pathway
led
describ
vlp
selfadjuv
immunogen
deliveri
system
howev
statement
temper
fact
vlpbase
candid
vaccin
requir
formul
potent
adjuv
order
induc
effici
immun
respons
indic
rel
abil
divers
vlp
type
induc
differ
branch
immun
respons
influenc
number
factor
vlpspecif
overal
vlp
shown
stimul
strong
bcellmedi
immun
respons
highli
effect
stimul
cell
prolif
respons
cytotox
lymphocyt
ctl
respons
fundament
goal
vaccin
immun
system
multipl
mechan
robustli
respond
viru
particl
may
exploit
vlpbase
vaccin
practic
term
mean
lower
dose
antigen
rel
monomer
antigen
vaccin
suffici
elicit
similar
protect
respons
consider
particularli
signific
case
veterinari
vaccin
cost
vaccin
must
weigh
valu
vaccin
anim
term
safeti
fact
vlp
lack
viral
nucleic
acid
complet
abolish
risk
associ
viru
replic
insert
revers
recombin
reassort
process
vlpbase
vaccin
prepar
without
need
propag
pathogen
virus
use
differ
express
system
henc
safeti
issu
associ
wholeviru
vaccin
product
administr
relat
viru
escap
product
facil
emerg
revers
mutant
effect
immunocompromis
individu
obviat
previous
report
vlp
produc
wide
rang
taxonom
structur
distinct
virus
infect
human
anim
well
plant
virus
compris
virus
singl
capsid
protein
multipl
capsid
protein
without
lipid
envelop
indic
abil
develop
vlp
appear
limit
type
viru
famili
complex
viru
particl
vlp
deriv
virus
lipid
envelop
like
influenza
viru
sometim
refer
virosom
consist
unilamelar
likeliposom
carri
viral
envelop
protein
addit
suitabl
vaccin
homolog
viru
deriv
vlp
also
use
platform
induc
immun
respons
antigen
choic
enhanc
broaden
potenti
use
prophylact
therapeut
vaccin
poor
immun
respons
mani
solubl
antigen
overcom
render
highli
repetit
singl
particl
achiev
incorpor
antigen
epitop
vlp
genet
fusion
chimer
vlp
conjug
antigen
vlp
develop
recombin
dna
engin
techniqu
combin
wealth
high
resolut
viral
structur
inform
facilit
abil
modifi
vlp
deliber
function
essenti
molecular
scaffold
present
genet
insert
foreign
antigen
vlp
deriv
doubleandsinglestrand
dna
rna
virus
encompass
differ
famili
viru
success
use
product
chimer
vlp
altern
approach
display
antigen
surfac
vlp
use
modular
system
nativ
vlp
target
antigen
synthes
separ
conjug
vitro
coval
noncoval
link
antigen
surfac
preassembl
vlp
conjug
techniqu
reli
presenc
address
moieti
surfac
vlp
need
vlp
engin
contain
use
attach
site
surfac
particl
advantag
approach
size
structur
recombin
target
antigen
constrain
requir
correct
fold
vlp
monom
particl
assembl
chemic
conjug
allow
attach
vlp
divers
kind
target
antigen
short
linear
peptid
cyclic
peptid
fulllength
protein
nonprotein
target
glycan
small
hapten
moreov
abil
vlp
spontan
assembl
allow
disassembl
reassembl
vitro
process
enabl
incorpor
differ
rang
molecul
within
vlp
particl
exampl
stimul
innat
immun
tlr
ligand
packag
within
vlp
way
codeliveri
antigen
activ
innat
immun
dc
enabl
subsequ
induct
effici
tcell
respons
thu
direct
adapt
immun
respons
appropri
magnitud
qualiti
specif
anoth
studi
highlight
recent
interest
develop
vlp
anim
virus
effect
drug
deliveri
system
anticanc
drug
doxorubicin
dox
coval
conjug
rotavirusbas
vlp
dvlp
produc
escherichia
coli
protein
express
system
dvlp
link
lactobion
acid
la
cellular
target
ligand
contain
galactos
dvlpla
intracellular
uptak
differ
cell
examin
zhao
et
al
demonstr
releas
dox
cell
differ
kinet
lower
toxic
system
compar
free
dox
vlp
act
carrier
antigen
deriv
microbi
pathogen
prophylact
vaccin
also
success
use
present
selfantigen
immun
system
overcom
bcell
toler
thu
open
way
develop
therapeut
vaccin
chronic
diseas
arthriti
alzheim
diseas
cancer
final
fact
vlp
contain
nonstructur
viral
protein
render
compat
diva
strategi
long
structur
protein
compos
vlp
use
marker
repres
import
potenti
use
vlpbase
vaccin
notifi
diseas
livestock
applic
diva
technolog
allow
compat
surveil
vaccin
program
allow
vaccin
play
signific
role
control
diseas
current
vlpbase
vaccin
human
diseas
variou
stage
develop
span
preclin
evalu
market
vaccin
hepat
b
recombivax
engerix
human
papillomaviru
gardasil
cervarix
licens
commerci
vaccin
clinic
develop
includ
type
vlp
repres
target
antigen
vlp
use
present
foreign
antigen
immun
system
veterinari
field
although
sever
candid
vaccin
cours
studi
tabl
porcin
circoviru
type
vlpbase
vaccin
porcili
pcv
manufactur
intervet
intern
netherland
licens
commerci
avail
member
circovirida
famili
associ
postwean
multisystem
wast
syndrom
swine
diseas
character
wast
weight
loss
respiratori
distress
diarrhea
sever
econom
impact
product
immunogen
porcili
pcv
vlp
form
capsid
protein
produc
use
baculoviru
express
system
vaccin
safe
highli
immunogen
effect
infect
shown
induc
humor
cellmedi
immun
protect
porcin
circovirusassoci
diseas
field
condit
one
intramuscular
dose
moreov
induc
broad
immun
protect
differ
genotyp
variou
geograph
isol
viru
anoth
similar
baculoviru
express
subunit
vaccin
ingelvac
circoflex
boehring
ingelheim
germani
licens
also
base
express
capsid
protein
inform
avail
whether
recombin
protein
assembl
vlp
swine
virus
investig
candid
develop
vlpbase
vaccin
one
first
studi
one
porcin
parvoviru
ppv
highli
infecti
viru
caus
reproduct
failur
pig
ppvvlp
protein
test
differ
anim
model
administr
singl
intramuscular
immun
coupl
differ
adjuv
microgram
dose
highli
immunogen
effici
prevent
transplacent
viru
transmiss
gilt
protect
ppvinduc
reproduct
failur
thu
parvoririda
shown
suitabl
viru
famili
gener
vlpbase
vaccin
inde
canin
parvoviru
cpv
protein
muscovi
duck
parvoviru
dpv
vp
protein
goos
parvoviru
gpv
vp
protein
mink
enter
viru
mev
protein
vlp
also
studi
vaccin
candid
recent
preliminari
studi
gees
gpvvlp
inject
subcutan
shown
higher
titer
neutral
antibodi
compar
inactiv
attenu
viru
vivo
likewis
previou
studi
duck
also
shown
product
specif
dpvantibodi
dpvvlp
immun
neutral
antibodi
level
consist
observ
duckl
inocul
commerci
inactiv
vaccin
also
mevvlp
shown
elicit
higher
antibodi
respons
revaccin
compar
commerci
convent
vaccin
interestingli
mink
protect
viral
challeng
excret
mev
fece
addit
two
studi
use
recombin
cpvvlp
primeboost
strategi
adjuv
test
vlp
abl
elicit
neutral
antibodi
suffici
render
immun
dog
protect
viral
challeng
influenza
viru
zoonosi
remain
one
major
threat
human
health
involv
wide
rang
anim
speci
mainli
avian
pig
hors
influenzavlp
fluvlp
assembl
produc
cell
infect
recombin
baculoviru
releas
cultur
medium
mimick
viral
bud
process
vlp
incorpor
viral
glycoprotein
hemaglutinin
neuraminidas
surfac
usual
viral
structur
protein
like
matrix
protein
ion
channel
protein
fluvlp
demonstr
provid
protect
immun
via
either
intranas
intramuscular
rout
absenc
adjuv
exhaust
review
fluvlp
gener
use
baculoviru
express
system
clinic
trial
human
addit
recent
studi
shown
pandem
vlp
immunogen
provid
protect
immun
pig
vlpbase
candid
vaccin
produc
import
zoonot
agent
deriv
rift
valley
fever
viru
rvfv
member
bunyavirida
famili
rvfv
transmit
sever
mosquito
speci
broad
rang
suscept
anim
host
interestingli
rvfvvlp
n
g
n
g
c
produc
mammalian
cell
abl
elicit
high
titer
neutral
antibodi
protect
mice
lethal
challeng
abolish
viru
replic
reovirida
rotavirus
rv
form
part
reovirida
famili
virus
widespread
among
newborn
mani
mammalian
speci
caus
sever
dehydr
diarrhea
rvvlp
express
main
structur
viral
protein
vp
assess
efficaci
use
differ
anim
model
mice
rabbit
gnotobiot
piglet
cow
use
parenter
rout
rvvlp
proven
confer
homolog
protect
rabbit
heterolog
protect
mice
moreov
homolog
heterolog
vlp
shown
immunogen
mice
differ
level
protect
report
depend
dose
rout
coadministr
adjuv
vlpbase
candid
vaccin
famili
gener
bluetongu
viru
btv
bt
vectorborn
diseas
rumin
caus
hemorrhag
ulcer
oral
caviti
upper
gastrointestin
tract
immunogen
btvvlp
obtain
baculoviru
express
system
develop
simultan
express
four
major
structur
protein
review
recent
comparison
btv
candid
vaccin
btvvlp
administ
presenc
variou
adjuv
sheep
vertebr
host
suscept
viru
result
indic
multiprotein
vlp
conjunct
appropri
adjuv
elicit
immun
respons
protect
infecti
viru
challeng
combin
differ
outer
capsid
protein
elicit
higher
neutralizingantibodi
titer
compar
protein
alon
addit
recent
studi
shown
outer
capsid
essenti
complet
protect
geograph
origin
btv
critic
develop
serotyp
specif
vaccin
papillomavirus
import
human
health
also
veterinari
field
inde
hors
donkey
cattl
develop
local
skin
tumor
term
sarcoid
dog
present
oral
papilloma
recent
studi
shown
intramuscular
vaccin
hors
bovin
papillomaviru
result
longlast
antibodi
respons
viru
neutral
titer
induc
level
correl
protect
experiment
anim
man
induct
protect
immun
respons
also
previous
report
cattl
review
ref
rabbit
cottontail
rabbit
papillomaviru
crpv
dog
canin
oral
papillomaviru
calicivirida
final
anoth
import
viru
famili
vlp
gener
calicivirida
calicivirus
includ
import
human
anim
pathogen
classifi
differ
genera
norovirus
main
caus
gastroenter
human
worldwid
also
describ
livestock
speci
rais
concern
regard
zoonot
potenti
rabbit
hemorrhag
diseas
viru
rhdv
prototyp
strain
genu
lagoviru
caus
agent
acut
highli
contagi
diseas
rabbit
decim
wild
domest
rabbit
popul
world
within
genu
vesiviru
felin
caliciviru
fcv
caus
respiratori
ill
cat
last
year
sporad
report
highli
virul
outbreak
fcv
diseas
cat
recombin
vlp
deriv
singl
capsid
protein
calicivirus
belong
differ
genera
develop
candid
vaccin
report
vlp
deriv
human
norovirus
use
induc
system
mucos
immun
respons
mice
evalu
human
clinic
trial
norovirusderiv
vlp
also
use
immun
calv
pig
induc
partial
protect
viru
challeng
better
result
obtain
vlpbase
vaccin
candid
rhdv
rhdvvlp
adjuv
inject
rabbit
differ
day
lethal
challeng
immun
abl
protect
rabbit
virul
challeng
condit
use
commerci
vaccin
test
franc
antibodi
specif
rhdv
capsid
protein
could
detect
earli
day
vaccin
titer
progress
increas
period
author
also
report
complet
protect
rabbit
rhdv
lethal
challeng
induc
rhdvvlp
similarli
fcvvlp
test
rabbit
immun
twice
vlp
adjuv
measur
neutral
antibodi
respons
detect
follow
first
immun
increas
boost
neutral
antibodi
titer
remain
high
throughout
month
sera
exhibit
neutral
activ
fcv
strain
analyz
picornavirida
virus
picornavirida
famili
share
common
replic
strategi
selfassembl
matur
capsid
protein
vlp
properti
shown
sever
picornavirus
includ
equin
rhiniti
viru
erav
foot
mouth
diseas
viru
fmdv
porcin
encephalomyocard
viru
emcv
vlp
gener
coexpress
viral
protein
polyprotein
nonstructur
protein
proteas
use
differ
express
system
eravvlp
gener
use
mammalian
express
vector
wherea
vlp
gener
use
baculoviru
express
system
erav
respiratori
pathogen
hors
may
caus
acut
febril
respiratori
diseas
subclin
infect
eravvlp
test
intramuscularli
mice
three
dose
follow
boost
uvinactiv
erav
vlpimmun
anim
show
signific
titer
virusneutr
antibodi
well
induct
memori
respons
neutral
epitop
fmdv
caus
econom
import
diseas
affect
pig
cattl
clovenhoof
livestock
fmdvvlp
test
guinea
pig
anim
immun
twice
vlp
adjuv
fmdvspecif
antibodi
neutral
antibodi
gener
vlpimmun
anim
level
lower
induc
convent
commerci
vaccin
probabl
poor
result
obtain
fmdvvlp
due
known
low
stabil
render
notori
difficult
obtain
usual
limit
yield
emcv
caus
myocard
prewean
pig
sever
reproduct
failur
sow
emcvvlp
test
natur
host
inocul
twice
use
adjuv
immun
elicit
neutral
antibodi
level
similar
obtain
administr
commerci
vaccin
studi
primeboost
strategi
effect
singledos
immun
induc
product
mainten
neutral
antibodi
poultri
industri
also
anoth
veterinari
field
search
safe
immunogen
protect
less
expens
vaccin
henc
econom
import
avian
virus
consid
potenti
target
develop
subunit
vaccin
chicken
anemia
viru
cav
belong
circovirida
famili
caus
anemia
immunodefici
newli
hatch
chicken
import
econom
loss
cav
protein
express
insect
cell
use
immun
chicken
immun
protein
abl
elicit
neutral
antibodi
progeni
immun
chicken
shown
protect
challeng
cav
directli
hatch
case
format
cavvlp
presum
confirm
anoth
import
diseas
affect
chicken
caus
infecti
bursal
diseas
viru
ibdv
birnavirida
viru
induc
immunosuppress
destruct
immatur
blymphocyt
within
bursa
fabriciu
variou
ibdvparticl
vpx
pp
deriv
polyprotein
differenti
process
test
chicken
use
one
dose
result
establish
ibdvvlp
effect
induc
humor
respons
elicit
virusneutr
capac
confer
protect
vaccin
chicken
commerci
vaccin
clear
vaccin
antigen
doseeffect
observ
interest
vlpbase
vaccin
candid
poultri
report
recent
vlp
form
structur
protein
np
f
hn
newcastl
diseas
viru
ndv
avian
envelop
paramyxoviru
caus
respiratori
andor
nervou
diseas
test
murin
model
comparison
uvinactiv
wholeviru
vaccin
vlp
demonstr
effect
immunogen
level
specif
antibodi
character
elisa
well
neutral
antibodi
titer
result
ndvvlp
immun
high
even
higher
result
immun
inactiv
wholeviru
vaccin
use
compar
amount
antigen
furthermor
ndvvlp
stimul
tcell
respons
level
slightli
higher
stimul
convent
vaccin
anoth
import
find
ndvvlp
also
use
platform
present
peptid
sequenc
target
pathogen
topic
comment
next
section
viral
fish
diseas
also
import
veterinari
field
sinc
creat
seriou
problem
piscicultur
seafood
market
great
econom
impact
nervou
necrosi
viru
nnv
nodavirida
famili
caus
encephalopathi
retinopathi
mani
speci
fish
vlp
deriv
singl
capsid
protein
virus
belong
genu
betanodaviru
gener
vaccin
candid
differ
fish
speci
two
studi
shown
vlp
abl
elicit
neutral
antibodi
nnv
respons
shown
dose
depend
addit
thieri
et
al
could
demonstr
vaccin
nnvvlp
abl
protect
fish
lethal
challeng
reduc
viru
spread
previous
indic
vlp
also
use
platform
multimer
display
foreign
antigen
incorpor
vlp
either
genet
fusion
chemic
conjug
case
vlp
serv
scaffold
present
antigen
deriv
pathogen
suitabl
repetit
configur
adjuv
boost
immun
respons
ideal
underli
immunogen
viral
fingerprint
vlp
impart
attach
antigen
make
potent
immunogen
vlp
section
review
vlp
deriv
human
anim
virus
use
vaccin
vector
present
antigen
virus
caus
anim
diseas
summar
tabl
one
first
vlp
use
vector
display
foreign
viral
antigen
one
deriv
hepat
b
viru
hbv
belong
hepadnavirida
famili
caus
agent
import
diseas
cirrhosi
andor
liver
cancer
human
neutral
epitop
deriv
protein
fmdv
fuse
hbv
core
antigen
protein
hbcag
result
chimer
vlp
elicit
virusneutr
antibodi
fmdv
induc
stronger
immun
respons
correspond
fmdvpeptid
immun
guinea
pig
furthermor
chimer
vlp
almost
immunogen
inactiv
fmdv
particl
vlpimmun
guinea
pig
complet
protect
challeng
fmdv
sever
studi
report
gener
chimer
hbcagderiv
vlp
incorpor
fmdv
antigen
epitop
vaccin
candid
use
differ
approach
beesley
et
al
produc
chimer
vlp
use
yeast
express
system
jin
et
al
use
system
base
transient
express
dna
plasmid
hela
cellcultur
result
obtain
studi
illustr
potenti
util
vaccin
strategi
fmdv
hbcagbas
vlp
also
use
express
differ
epitop
mhci
mhcii
restrict
peptid
lymphocyt
choriomening
viru
lcmv
rodentborn
viru
studi
perform
order
investig
preexist
vlpspecif
antibodi
could
interfer
specif
cytotox
tcell
thcell
respons
induct
protect
respons
mice
model
antigen
present
significantli
affect
either
vitro
vivo
presenc
antibodi
vlp
scaffold
protect
immun
could
establish
carriervaccin
anim
thu
ruedl
et
al
open
new
perspect
around
vlp
vector
classic
concept
previou
immun
matern
antibodi
impair
induct
protect
immun
respons
upon
vaccin
inde
also
veterinari
field
interfer
colostr
antibodi
describ
vaccin
anim
howev
result
report
ruedl
et
al
suggest
preexist
vlpspecif
antibodi
unlik
limit
factor
vlpbase
tcell
vaccin
although
studi
need
perform
veterinari
speci
fulli
clarifi
aspect
also
storni
et
al
use
hbcag
express
lcmv
epitop
investig
activ
apc
prime
ctl
respons
vlp
vaccin
model
demonstr
vlp
alon
ineffici
induc
ctl
respons
fail
mediat
effect
protect
form
viral
challeng
becam
power
appli
togeth
substanc
activ
apc
eg
antibodi
cpg
recent
confirm
hbv
promis
deliveri
vehicl
publish
wang
et
al
use
vlp
hbc
contain
five
mimotop
ibdv
studi
chicken
immun
intramuscularli
four
dose
vlp
immun
adjuv
confer
protect
challeng
virul
strain
ibdv
vlp
deriv
member
polyomavirida
famili
also
amen
develop
vaccin
vector
polyomavirus
pyv
differ
speci
use
display
viral
epitop
tumor
antigen
hamster
pyvvlp
incorpor
ctl
epitop
deriv
lcmv
shown
elicit
specif
protect
memori
ctl
respons
vivo
without
adjuv
moreov
aggress
growth
tumor
express
significantli
delay
mice
vivo
likewis
murin
pyvvlp
display
entir
human
prostat
specif
antigen
psa
use
immun
therapi
mous
model
system
eriksson
et
al
demonstr
psampyvlp
load
onto
dc
presenc
cpg
protect
mice
tumor
outgrowth
wherea
chimer
vlp
alon
without
adjuv
margin
protect
mice
load
vlp
onto
dc
open
new
perspect
vlpbase
vaccin
reduc
antivlp
antibodi
respons
favor
primeboost
therapi
parvoviru
deriv
vlp
also
use
scaffold
foreign
antigen
present
sedlik
et
al
gener
recombin
ppvvlp
incorpor
ctl
epitop
lcmv
nucleoprotein
epitop
fuse
nterminu
capsid
protein
ppv
result
chimer
vlp
analyz
immunogen
mice
one
intraperiton
immun
g
ppvlcmvvlp
abl
induc
complet
protect
mice
lethal
lcmv
challeng
induct
virusspecif
mhcirestrict
ctl
protect
requir
helper
function
neither
adjuv
strong
vivo
ctl
respons
induc
chimer
vlp
persist
month
immun
ppvvlp
also
use
display
immunoreact
epitop
deriv
nucleoprotein
elicit
strong
antibodi
respons
mice
absenc
adjuv
calicivirida
anoth
promis
vlp
system
conveni
foreign
antigen
display
base
rhdvvlp
group
identifi
three
site
suitabl
insert
heterolog
immunogen
epitop
within
rhdv
capsid
protein
gener
recombin
chimer
rhdvvlp
incorpor
mhcirestrict
tcell
epitop
siinfekl
deriv
chicken
ovalbumin
ova
foreign
epitop
insert
two
differ
locat
nterminu
predict
expos
loop
viral
capsid
protein
correspond
chimer
vlp
test
immunogen
mous
model
vitro
result
show
rhdvvlp
activ
dc
abl
process
present
foreign
epitop
specif
recognit
dosedepend
manner
vivo
absenc
adjuv
chimer
rhdvvlp
abl
stimul
specif
cell
prime
power
ctl
respons
mainli
foreign
epitop
insert
nterminu
rhdv
capsid
protein
mice
immun
twice
chimer
rhdvvlp
abl
control
infect
recombin
vaccinia
viru
express
ova
target
organ
similar
result
report
group
use
rhdvvlp
display
ovaderiv
epitop
incorpor
chemic
conjug
studi
conjug
rhdvvlp
administ
adjuv
cpg
test
antitumor
respons
mous
model
result
obtain
indic
vaccin
conjug
vlp
result
signific
reduct
tumor
growth
chimer
rhdvvlp
also
shown
effici
vaccin
vector
immun
pig
elicit
strong
humor
cellular
respons
insert
foreign
epitop
deriv
fmdv
anoth
report
use
chimer
rhdvvlp
gene
transfer
vector
chimer
rhdvvlp
harbor
dnabind
sequenc
deriv
human
papillomaviru
abl
packag
plasmid
dna
thu
transfer
gene
anim
cell
open
way
altern
method
gene
transfer
mention
previou
section
ndvvlp
vlp
contain
np
f
hn
viral
protein
also
use
display
peptid
sequenc
deriv
target
pathogen
incorpor
genet
fusion
either
termin
end
np
protein
cterminu
hn
glycoprotein
importantli
ndvvlp
use
present
entir
ectodomain
glycoprotein
virus
ndv
glycoprotein
assembl
vlp
owe
specif
interact
glycoprotein
cytoplasm
ct
transmembran
tm
domain
viru
core
protein
incorpor
foreign
glycoprotein
ectodomain
ndvvlp
achiev
gener
chimer
protein
gene
compos
sequenc
encod
foreign
protein
ectodomain
fuse
encod
tm
ct
domain
appropri
ndv
glycoprotein
use
approach
entir
ectodomain
nipah
viru
g
influenza
viru
respiratori
syncyti
viru
rsv
success
insert
ndvvlp
interest
result
immun
ndvvlp
contain
ectodomain
rsv
g
protein
provid
complet
protect
rsv
replic
lung
intranas
challeng
live
viru
murin
system
furthermor
approach
enabl
incorpor
singl
particl
prepar
ectodomain
deriv
two
differ
virus
rais
possibl
use
ndvvlp
singl
vaccin
two
differ
pathogen
exampl
assembl
ndv
hn
protein
influenza
ha
protein
singl
vlp
could
use
protect
chicken
avian
influenza
ndv
although
dival
vaccin
report
yet
vlp
use
vaccin
sinc
late
despit
long
histori
date
hand
vlpbase
vaccin
current
commerci
worldwid
sever
vlpbase
vaccin
candid
undergo
clinic
trial
mani
other
still
restrict
smallscal
fundament
research
despit
accumul
evid
potenti
vlp
potent
immunogen
mani
viral
diseas
human
anim
current
limit
applic
part
due
technic
practic
challeng
associ
largescal
vlp
product
process
although
vlp
produc
wide
rang
virus
clearli
equal
suitabl
develop
vaccin
even
proofofconcept
demonstr
support
strong
preclin
data
vlpbase
product
candid
could
develop
vaccin
widespread
use
manufactur
process
scalabl
costeffect
vlp
made
assembl
singl
protein
usual
abl
produc
larg
amount
high
qualiti
structur
complex
vlp
instanc
rais
difficulti
larg
scale
product
addit
due
inher
properti
lipid
envelop
product
envelop
vlp
technic
complex
howev
progress
made
expect
near
futur
integr
process
optim
tool
ie
molecular
biolog
genet
engin
system
biolog
overcom
current
limit
affect
larg
scale
product
sever
type
vlp
vlp
produc
differ
express
system
includ
bacteri
yeast
mammalian
plant
cell
howev
popular
choic
express
insect
cell
use
recombin
baculoviru
technolog
express
system
mani
advantag
vlp
product
recent
review
see
larg
amount
correctli
fold
recombin
protein
produc
eukaryoticlik
posttransl
modif
although
yeast
bacteria
cell
achiev
similar
yield
complex
vlp
produc
baculoviru
express
system
remark
higher
vlp
form
five
protein
addit
advantag
baculovirus
limit
host
rang
name
insect
henc
safe
vertebr
insect
cell
use
baculoviru
express
system
deriv
lepidopteran
insect
rel
easi
grow
grow
serumfre
media
cultur
easili
scale
design
recombin
baculovirus
simpl
fast
provid
high
versatil
express
system
import
produc
vaccin
virus
whose
surfac
protein
rapidli
mutat
eg
influenza
viru
fundament
requir
contend
potenti
pandem
time
manner
nevertheless
express
system
present
import
drawback
one
main
limit
signific
coproduct
infect
baculoviru
particl
difficult
separ
vlp
baculoviru
particl
interfer
immunogen
vlpbase
vaccin
furthermor
potenti
contamin
vlp
prepar
infect
recombin
baculovirus
rais
environment
concern
reason
vlpbase
immunogen
produc
baculoviru
express
system
must
undergo
either
chemic
inactiv
treatment
elimin
baculoviru
infect
may
impair
qualiti
produc
vlp
sever
downstream
biosepar
process
step
may
increas
final
product
cost
respect
promis
novel
approach
recent
report
might
greatli
simplifi
downstream
process
biopharmaceut
produc
insect
cell
new
strategi
base
use
recombin
baculovirus
lack
gene
essenti
viru
format
affect
foreign
gene
express
delet
transcompl
transgen
insect
cell
line
use
gener
baculoviru
seed
stock
result
defect
baculovirus
use
produc
larg
amount
recombin
protein
without
contamin
virion
mention
problem
hamper
time
develop
vaccin
produc
insect
cell
manufactur
platform
howev
market
author
two
vaccin
veterinari
applic
porcili
pesti
bayonac
csf
classic
swine
fever
viru
year
afterward
commerci
licens
vlpbase
vaccin
cervarix
human
use
critic
mileston
regulatori
accept
insect
cell
technolog
manufactur
vaccin
nowaday
technolog
shown
meet
econom
requir
manufactur
modern
vaccin
larg
popul
current
domin
platform
product
veterinari
vaccin
thu
pave
way
licens
mani
vlpbase
vaccin
anim
use
regard
use
vlp
foreign
epitop
display
platform
strategi
gener
chimer
vlp
genet
fusion
chemic
conjug
antigen
vlp
pose
limit
order
induc
hightit
antibodi
respons
effect
target
antigen
must
display
surfac
vlp
immunodomin
region
high
densiti
consequ
one
key
point
gener
chimer
vlp
select
suitabl
insert
site
must
present
surfac
vlp
interfer
protein
fold
assembl
howev
gener
chimer
vlp
larg
empir
almost
imposs
predict
whether
individu
peptid
compat
vlp
assembl
whether
insert
immunogen
anoth
import
limit
chimer
approach
size
natur
epitop
insert
vlp
particular
immunodomin
region
restrict
vlp
contain
peptid
longer
amino
acid
often
fail
assembl
rel
larg
insert
success
incorpor
vlp
tend
except
rule
size
limit
restrict
number
epitop
target
individu
chimer
vlp
contrast
flexibl
altern
approach
base
chemic
conjug
target
antigen
previous
assembl
nativ
vlp
offer
substanti
advantag
although
depend
access
address
residu
vlp
target
antigen
hand
manufactur
standpoint
genet
fusion
approach
may
advantag
chemic
conjug
sinc
chimer
vlp
produc
purifi
use
wellestablish
method
use
purifi
unmodifi
parent
vlp
wherea
product
process
conjug
vlp
entail
extra
challeng
qualiti
control
method
inevit
complex
vlp
foreign
epitop
display
strategi
typic
permit
epitop
limit
size
target
sinc
pathogen
usual
undergo
antigen
variat
respons
host
immun
pressur
vaccin
base
vlp
display
foreign
epitop
effect
highli
conserv
bor
tcell
epitop
consequ
vlp
appear
best
suit
target
highli
conserv
antigen
exampl
appropri
target
acid
extracellular
domain
protein
influenza
viru
highli
conserv
among
viral
strain
shown
induc
protect
mice
lethal
challeng
upon
administr
peptid
incorpor
hbvderiv
vlp
indic
previou
section
rel
abil
divers
vlp
type
induc
differ
branch
immun
respons
influenc
number
factor
vlpspecif
therefor
appear
unlik
singl
vlp
platform
meet
desir
requir
howev
continu
parallel
develop
multipl
vlp
platform
ensur
individu
vaccin
tailor
appropri
type
immun
respons
requir
case
vlp
appeal
vaccin
candid
inher
properti
ie
multimer
antigen
particul
structur
infecti
suitabl
induct
safe
effici
humor
cellular
immun
respons
fact
vlpbase
vaccin
may
compli
diva
requir
make
even
attract
vaccin
develop
veterinari
field
current
clear
trend
toward
establish
vlp
power
tool
vaccin
develop
human
vaccin
market
five
alreadi
vlpbase
three
hbv
two
hpv
veterinari
field
vlpbase
vaccin
recent
licens
sever
vlp
vaccin
candid
target
human
anim
diseas
current
late
stage
evalu
moreov
develop
vlp
platform
foreign
antigen
display
broaden
potenti
applic
prophylact
therapeut
vaccin
new
approach
still
challeng
overcom
relat
manufactur
process
gener
chimer
vlp
recent
result
area
howev
encourag
underscor
versatil
vlpbase
technolog
applic
develop
new
gener
vaccin
